Can a diabetes pill fix antipsychotic weight gain?

NCT ID NCT05669742

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding empagliflozin, a diabetes drug, can reduce weight gain and other metabolic side effects caused by olanzapine in people with schizophrenia. Forty adults aged 18 to 60 who take olanzapine will receive either empagliflozin or a placebo for several weeks. The main goal is to see if the drug helps control body weight and BMI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Empagliflozin

What this could lead to

If it works, this could offer a way to manage weight gain and metabolic problems caused by olanzapine, making the antipsychotic safer and easier to tolerate.

What could go wrong

This is a small early-phase trial with only 40 participants, so results may not apply broadly. The drug may not reduce weight gain significantly, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tanta Unuversity

    RECRUITING

    Tanta, 34518, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••